摘要
RET原癌基因已经逐渐被证实与多种恶性肿瘤的发生、发展具有相关性,伴着分子靶向研究的热潮,RET基因的融合突变在肺癌患者中被发现,提示肺癌精准治疗的新靶点出现。RET突变更易出现于较年轻、分化程度较低、非吸烟的非小细胞肺腺癌患者。靶向治疗由于对致癌基因的特异性阻断,可以有效地抑制肿瘤细胞的生长,而RET抑制剂的问世,为肺癌分子治疗研究领域带来新的曙光。
RET proto-oncogene has gradually been associated with the occurrence and development of a variety of malignant tumors, along with the upsurge of molecular targeted study, the fusion mutation of RET genes is found in lung cancer patients, suggesting a new target for the precision treatment of lung cancer. RET mutations are more likely to occur in the patients featured with non-small cell lung adenocarcinomas with younger age, less differentiated, non-smokers. Targeted therapy can effectively inhibit the growth of tumor cells with specific blocking oncogene. With the birth of RET irthibitors, molecular therapy of lung cancer may usher a new dawn.
出处
《医学综述》
2017年第3期474-478,共5页
Medical Recapitulate
基金
新疆医科大学科研创新基金(XYDCX201548)
关键词
非小细胞肺癌
RET基因
融合突变
靶向治疗
Non-small cell lung cancer
RET gene
Fusion mutation
Targeted therapy
